Serine Protease 56
Function[edit | edit source]
ME/CFS[edit | edit source]
The first publication from the long term ME/CFS Gene Study, which used the Fukuda criteria for chronic fatigue syndrome only, looked for the SNPs that were more common in CFS patients than in healthy people, and which were most likely to be harmful. PRSS56 was one of the top ten genes most likely to be harmful that more common in CFS patients, occurring in over 70% of patients.
Notable studies[edit | edit source]
- 2019, Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study(Full text)
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Nathanson, Lubov; Craddock, Travis J. A.; Klimas, Nancy G.; Gemayel, Kristina; Del Alamo, Ana; Hilton, Kelly; Jaundoo, Rajeev; Perez, Melanie (2019). "Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study". Frontiers in Pediatrics. 7: 206. doi:10.3389/fped.2019.00206. ISSN 2296-2360.
myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.